These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7625787)

  • 1. Effect of fluconazole on pharmacokinetics of 2',3'-dideoxyinosine in persons seropositive for human immunodeficiency virus.
    Bruzzese VL; Gillum JG; Israel DS; Johnson GL; Kaplowitz LG; Polk RE
    Antimicrob Agents Chemother; 1995 May; 39(5):1050-3. PubMed ID: 7625787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus.
    Knupp CA; Brater DC; Relue J; Barbhaiya RH
    J Clin Pharmacol; 1993 Oct; 33(10):912-7. PubMed ID: 8227460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.
    Cimoch PJ; Lavelle J; Pollard R; Griffy KG; Wong R; Tarnowski TL; Casserella S; Jung D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):227-34. PubMed ID: 9495222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.
    Gibb D; Barry M; Ormesher S; Nokes L; Seefried M; Giaquinto C; Back D
    Br J Clin Pharmacol; 1995 May; 39(5):527-30. PubMed ID: 7669489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus--infected pregnant women and their neonates: an AIDS clinical trials group study.
    Wang Y; Livingston E; Patil S; McKinney RE; Bardeguez AD; Gandia J; O'Sullivan MJ; Clax P; Huang S; Unadkat JD
    J Infect Dis; 1999 Nov; 180(5):1536-41. PubMed ID: 10515813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients.
    Borin MT; Cox SR; Herman BD; Carel BJ; Anderson RD; Freimuth WW
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1892-7. PubMed ID: 9303380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children.
    Balis FM; Pizzo PA; Butler KM; Hawkins ME; Brouwers P; Husson RN; Jacobsen F; Blaney SM; Gress J; Jarosinski P
    J Infect Dis; 1992 Jan; 165(1):99-104. PubMed ID: 1727902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I evaluation of concomitant rifabutin and didanosine in symptomatic HIV-infected patients.
    Sahai J; Narang PK; Hawley-Foss N; Li RC; Kamal M; Cameron DW
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):274-9. PubMed ID: 7788425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Didanosine.
    Shelton MJ; O'Donnell AM; Morse GD
    Ann Pharmacother; 1992 May; 26(5):660-70. PubMed ID: 1350471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.
    Barry M; Howe JL; Ormesher S; Back DJ; Breckenridge AM; Bergin C; Mulcahy F; Beeching N; Nye F
    Br J Clin Pharmacol; 1994 May; 37(5):421-6. PubMed ID: 8054247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.
    Japour AJ; Lertora JJ; Meehan PM; Erice A; Connor JD; Griffith BP; Clax PA; Holden-Wiltse J; Hussey S; Walesky M; Cooney E; Pollard R; Timpone J; McLaren C; Johanneson N; Wood K; Booth D; Bassiakos Y; Crumpacker CS
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Nov; 13(3):235-46. PubMed ID: 8898668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus.
    Knupp CA; Graziano FM; Dixon RM; Barbhaiya RH
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2075-9. PubMed ID: 1444287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates.
    Rongkavilit C; Thaithumyanon P; Chuenyam T; Damle BD; Limpongsanurak S; Boonrod C; Srigritsanapol A; Hassink EA; Hoetelmans RM; Cooper DA; Lange JM; Ruxrungtham K; Phanuphak P
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3585-90. PubMed ID: 11709344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.
    Lambert JS; Seidlin M; Reichman RC; Plank CS; Laverty M; Morse GD; Knupp C; McLaren C; Pettinelli C; Valentine FT
    N Engl J Med; 1990 May; 322(19):1333-40. PubMed ID: 2139173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus.
    Zhou XJ; Squires K; Pan-Zhou XR; Bernhard S; Agrofoglio L; Kirk M; Duchin KL; Sommadossi JP
    J Clin Pharmacol; 1997 Mar; 37(3):201-13. PubMed ID: 9089422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients.
    De Wit S; Debier M; De Smet M; McCrea J; Stone J; Carides A; Matthews C; Deutsch P; Clumeck N
    Antimicrob Agents Chemother; 1998 Feb; 42(2):223-7. PubMed ID: 9527763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic interaction between ritonavir and didanosine when administered concurrently to HIV-infected patients.
    Cato A; Qian J; Hsu A; Vomvouras S; Piergies AA; Leonard J; Granneman R
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(5):466-72. PubMed ID: 9715843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of 2',3'-dideoxyinosine (BMY-40900), a new anti-human immunodeficiency virus agent, after administration of single intravenous doses to beagle dogs.
    Kaul S; Knupp CA; Dandekar KA; Pittman KA; Barbhaiya RH
    Antimicrob Agents Chemother; 1991 Apr; 35(4):610-4. PubMed ID: 1906259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials.
    Drusano GL; Yuen GJ; Morse G; Cooley TP; Seidlin M; Lambert JS; Liebman HA; Valentine FT; Dolin R
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1280-3. PubMed ID: 1416828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus (HIV)-positive patients.
    Jung D; Griffy K; Dorr A; Raschke R; Tarnowski TL; Hulse J; Kates RE
    J Clin Pharmacol; 1998 Nov; 38(11):1057-62. PubMed ID: 9824788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.